Presently, close to 50 companies are offering a variety of analytical

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
 
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
 
The USD  860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
Type of test
Laboratory Developed Tests (LDTs)
Companion Diagnostic Tests (CDx)
Type of disease indication
Breast cancer
Blood cancer
Colon / Colorectal cancer
Lung Cancer
Melanoma
Prostate Cancer
Type of cancer biomarker
TMB
MSI / MMR
TILs
Type of analytical technique
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
Others
Key geographical regions
North America
Europe
Japan
China
Australia
 
The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain: 
  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology
 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


4. Current Market Landscape


5. Product Competitiveness Analysis


6. Company Profiles


7. Publication Analysis


8. Innovative Designs for Biomarker-Based Clinical Trials


9. Clinical Trial Analysis


10. Market Forecast


11. Future Growth Opportunities


12. Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry


13. Case Study: Analysis of Value Chain in the Companion Diagnostics Industry


14. Clinical Research on Cancer Biomarkers: A Big Pharma Perspective
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
 
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
390 Posts

Made with by Mamby